A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder-Reference-Cited by-同舟云学术

A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder

Published:2014-05 Issue:4 Volume:24 Page:180-189
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Atkinson Sarah D.¹,Prakash Apurva²,Zhang Qi²,Pangallo Beth A.²,Bangs Mark E.²,Emslie Graham J.³,March John S.⁴

Affiliation:

1. Finger Lakes Clinical Research, Rochester, New York.

2. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.

3. Child and Adolescent Psychiatry Division, University of Texas Southwestern and Children's Medical Center, Dallas, Texas.

4. Division of Neurosciences Medicine, Duke Clinical Research Institute, Duke University, Durham, North Carolina.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology, and Child Health

Link

http://www.liebertpub.com/doi/pdf/10.1089/cap.2013.0146

Reference18 articles.

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.

2. Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial

3. A Double-Blind Efficacy and Safety Study of Duloxetine Fixed Doses in Children and Adolescents with Major Depressive Disorder

4. A Double-blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Children and Adolescents With Depression

5. GuyW. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies;European Child & Adolescent Psychiatry;2024-09-06

2. Effects of selective serotonin reuptake inhibitors (SSRIs) on suicide: A network meta-analysis of double-blind randomized trials;Psychiatry Research;2024-06

3. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies;Journal of Child and Adolescent Psychopharmacology;2024-06-01

4. Integrating Pharmacotherapy into Brief Interventions for Child and Adolescent Treatment;CBT: Science Into Practice;2024

5. The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 2 – pharmacological properties and safety of use;Psychiatria Polska;2023-10-31